Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

GLIAMAC · Uncovering Enteric GLIA-MACrophage communication in the intestinal homeostasis and inflammation

H2020Status: CLOSED1 December 201830 November 2020EU funding €160,800Call H2020-MSCA-IF-2017

Uncovering Enteric GLIA-MACrophage communication in the intestinal homeostasis and inflammation.The enteric nervous system (ENS) is a network of neurons and enteric glial cells (EGCs) organized in ganglia essential to control gastrointestinal physiology. Although EGCs have historically been described as supporting cells for enteric neurons, recent data from my previous work and from my host group demonstrated that enteric glia is “communicating” with innate immune cells via the secretion of immune-active molecules. Interestingly, alterations in the morphology and function of EGCs have been reported in patients affected by chronic intestinal inflammation such as inflammatory bowel disease (IBD). Thus, I hypothesise that factors released by enteric GLIA may directly modulate MACrophage phenotype and function in the gut, making EGC a novel overlooked player in the pathophysiology of IBD. In the first part of GLIAMAC, the molecules and the molecular mechanisms involved in the enteric glia-macrophage crosstalk will be screened in vitro using co-culture experiments and assessed in vivo using novel EGC-specific mouse models of intestinal inflammation. Finally, I aim to translate our findings to the clinical setting using tissue samples from IBD patients. To this end, the immunomodulatory properties of EGCs isolated from healthy individuals and IBD patients will be compared using cellular, genomic and proteomic system-wide approaches. Identification of new molecules and pathways involved in enteric glia-immune cell crosstalk will represent a major breakthrough in elucidating the pathogenesis of intestinal immune-mediated diseases. Thus, GLIAMAC will potentially give rise to a new class of molecules to treat and favour remission in patients affected by IBD.

Consortium · 1 organisation

coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €160,800

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.